Document is current
Any future updates will be listed below
-
Authors
Hopp, Christine S https://orcid.org/0000-0002-0528-9531
Kanatani, Sachie
Archer, Nathan K
Miller, Robert J
Liu, Haiyun
Chiou, Kevin K
Miller, Lloyd S
Sinnis, Photini https://orcid.org/0000-0003-2954-7547
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01 AI132359)
National Institutes of Health (R01AR069502)
National Institutes of Health (R01AR073665)
National Institutes of Health (K01AR073924)
Bloomberg Philanthropies
- License Information
-
More Information
Article History
Received: 20 November 2019
Revised: 21 January 2021
Accepted: 27 January 2021
First Online: 22 March 2021
Conflict of interest
: L. S. M. is a full‐time employee of Janssen Pharmaceuticals (a Johnson & Johnson Company) and holds Johnson & Johnson stock. L. S. M. performed all work at his prior affiliation at Johns Hopkins University School of Medicine, and he has received prior grant support from AstraZeneca, Pfizer, Boehringer Ingelheim, Regeneron Pharmaceuticals, and Moderna Therapeutics, was a paid consultant for Armirall and Janssen Research and Development, was on the scientific advisory board of Integrated Biotherapeutics and is a shareholder of Noveome Biotherapeutics, which are all developing therapeutics against infections and/or inflammatory conditions.
